The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
PAM50 intrinsic subtyping and pathologic responses to neoadjuvant trastuzumab-based chemotherapy in HER2-positive breast cancer.
P. Gomez Pardo
No relevant relationships to disclose
A. Prat
No relevant relationships to disclose
G. Bianchini
No relevant relationships to disclose
M. Pickl
Employment or Leadership Position - Roche
A. Belousov
Employment or Leadership Position - Roche
A. Koehler
Employment or Leadership Position - Roche
Stock Ownership - Roche
V. Semiglazov
No relevant relationships to disclose
W. Eiermann
No relevant relationships to disclose
S. Tjulandin
Honoraria - AstraZeneca; GlaxoSmithKline; Roche
M. Biakhov
No relevant relationships to disclose
A. Lluch
Honoraria - Roche
Other Remuneration - Roche
M. Zambetti
No relevant relationships to disclose
F. Vázquez-Mazón
No relevant relationships to disclose
L. Gianni
Consultant or Advisory Role - Genentech; GlaxoSmithKline; Novartis; Pfizer (U); Roche; Wyeth
J. Baselga
Consultant or Advisory Role - Roche